We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS on AGM very positive reading. Nice to see such a positive RNS . Hold long term and top up on the dips . All good.
We are red!!! Lol Just read the most upbeat annual report ever and we are red. The mms hoovering up the stop loses. How predictable.
Key words “Building long term sustainable share holder value”
The mms can tree shake all they like. I’m not going anywhere.
Good post Kevkan....
What newsflow might we expect from the Group during 2020?
Clearly there is going to be
a significant focus on the development and commercialisation of the COVID-19
diagnostic test during 2020 and we very much look forward to keeping the market updated. However, there
is considerable potential newsflow expected from our broader diagnostic and therapeutic programmes.
We will keep the market updated on the progress of AVA6000 into the clinic and
I hope that we will see
additional therapeutic partnerships established during the year. I expect to see continued growth in the
diagnostics business and we will be working extremely hard to convert the strong commercial interest there
is in the Affimer diagnostics platform into licensing deals and revenue growth.
"Outlook Avacta has, over the past few years, created huge potential value for shareholders through the establishment of multiple global partnerships and a pipeline of Affimer therapeutics and diagnostics. On top of that we have taken the therapeutics opportunity to the next level by adding the unique precision chemotherapy platform. The Group is now delivering this value to shareholders and is in a position to continue to do this in a long-term and sustainable manner. The planned phase I study of AVA6000 prodoxorubicin in cancer patients is transformational for the Group. If the pre-clinical performance of this drug is recapitulated in humans, then not only will AVA6000 have the potential to become a proprietary blockbuster in its own right, but the potential of the preCISION platform to improve the safety of a range of chemotherapies will have been demonstrated. This is a significant and unique opportunity for the Group to address urgent clinical needs in oncology through advanced chemotherapies and in combination with Affimer immunotherapies. The strong commercial progress in the Affimer diagnostics business unit is reflected in the number of technology evaluations and growing revenue. Very recently, a spotlight has been shone on the power of the Affimer platform to generate diagnostic reagents quickly and with high specificity by our success in generating diagnostic Affimers for the SARS-COV-2 antigen in our collaboration with Cytiva. We are focused on building long-term, sustainable growth in shareholder value based on the numerous therapeutic and diagnostic opportunities that the Group has created, including a COVID-19 rapid antigen test. I look forward very much to keeping the market up to date as we progress."
Spitting facts (as well as on a test strip)
"We believe that the technical risk of developing a COVID-19 diagnostic is significantly reduced now that we have a large number of Affimer reagents to work with, and our objective is to have a saliva test ready for production as early as possible in the summer. This individual opportunity is significant; there will be
a medium-term need for very high volume COVID-19 antigen testing to support the global process of exiting lockdown and getting healthy people back to work. There will also be a long-term need for antigen testing as the disease will remain in some societies for many years. Outside of this opportunity, which has raised the
profile of the Affimer platform dramatically, there remains significant commercial potential for Affimer diagnostics to deliver long-term sustainable revenues."